A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
(FRONTIER 1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called JNJ-77242113 to help people with severe psoriasis. It targets the immune system to reduce skin issues. The study focuses on those who do not respond well to standard treatments.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications before starting. If you've used specific psoriasis treatments like IL-23R, IL-17, IL-12/23, or TNF-alpha therapies, you need to stop them at least 12 weeks or 5 half-lives before the trial. B cell-depleting agents must be stopped 26 weeks prior.
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JNJ-77242113 or placebo for 16 weeks to evaluate efficacy and safety in moderate-to-severe plaque psoriasis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-77242113
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University